New York Comprehensive Thalassemia Center
Found 22 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is R  [Clear All Filters]
2021
Frangoul H, Altshuler D, M Cappellini D, Chen Y-S, Domm J, Eustace BK, Foell J, de la Fuente J, Grupp S, Handgretinger R et al..  2021.  CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.. N Engl J Med. 384(3):252-260.
Chonat S, Eber SW, Holzhauer S, Kollmar N, D Morton H, Glader B, Neufeld EJ, Yaish HM, Rothman JA, Sharma M et al..  2021.  Pyruvate kinase deficiency in children.. Pediatr Blood Cancer. 68(9):e29148.
Chonat S, Eber SW, Holzhauer S, Kollmar N, D Morton H, Glader B, Neufeld EJ, Yaish HM, Rothman JA, Sharma M et al..  2021.  Pyruvate kinase deficiency in children.. Pediatr Blood Cancer. 68(9):e29148.
2020
Al-Samkari H, van Beers EJ, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kuo KHM, Kollmar N et al..  2020.  Characterization of the severe phenotype of pyruvate kinase deficiency.. Am J Hematol.
Al-Samkari H, van Beers EJ, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kuo KHM, Kollmar N et al..  2020.  Characterization of the severe phenotype of pyruvate kinase deficiency.. Am J Hematol.
Al-Samkari H, van Beers EJ, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kuo KHM, Kollmar N et al..  2020.  Characterization of the severe phenotype of pyruvate kinase deficiency.. Am J Hematol.
Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.
Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.
Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.
Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.
Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.
Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.
2019
van Beers EJ, van Straaten S, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kwiatkowski JL, Rothman JA et al..  2019.  Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study.. Haematologica. 104(2):e51-e53.
van Beers EJ, van Straaten S, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kwiatkowski JL, Rothman JA et al..  2019.  Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study.. Haematologica. 104(2):e51-e53.
van Beers EJ, van Straaten S, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kwiatkowski JL, Rothman JA et al..  2019.  Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study.. Haematologica. 104(2):e51-e53.
Grace RF, Rose C, D Layton M, Galactéros F, Barcellini W, D Morton H, van Beers EJ, Yaish H, Ravindranath Y, Kuo KHM et al..  2019.  Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.. N Engl J Med. 381(10):933-944.
Grace RF, Rose C, D Layton M, Galactéros F, Barcellini W, D Morton H, van Beers EJ, Yaish H, Ravindranath Y, Kuo KHM et al..  2019.  Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.. N Engl J Med. 381(10):933-944.
2018
Grace RF, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM, Despotovic JM, Rothman JA, Sharma M, McNaull MM et al..  2018.  Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.. Blood. 131(20):2183-2192.
Grace RF, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM, Despotovic JM, Rothman JA, Sharma M, McNaull MM et al..  2018.  Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.. Blood. 131(20):2183-2192.
Grace RF, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM, Despotovic JM, Rothman JA, Sharma M, McNaull MM et al..  2018.  Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.. Blood. 131(20):2183-2192.
2017
Rapido F, Brittenham GM, Bandyopadhyay S, La Carpia F, L'Acqua C, McMahon DJ, Rebbaa A, Wojczyk BS, Netterwald J, Wang H et al..  2017.  Prolonged Red Cell Storage Before Transfusion Increases Extravascular Hemolysis. J Clin Invest. 127(1):375-382.
Rapido F, Brittenham GM, Bandyopadhyay S, La Carpia F, L'Acqua C, McMahon DJ, Rebbaa A, Wojczyk BS, Netterwald J, Wang H et al..  2017.  Prolonged Red Cell Storage Before Transfusion Increases Extravascular Hemolysis. J Clin Invest. 127(1):375-382.